A Subunit Vaccine Against Acinetobacter Baumannii

Project Title: Development of a Novel Vaccine against Multi-Drug Resistant Acinetobacter baumannii Abstract: The escalating threat of Multi-Drug Resistant Acinetobacter baumannii (MDR-AB) represents a significant challenge to global health, underscoring the urgent need for effective preventive measures. This SBIR Phase I project aims to develop a novel vaccine candidate that stimulates immune protection against MDR-AB, addressing a critical gap in our current arsenal against antibiotic-resistant infections. Leveraging a multidisciplinary approach, our project integrates advanced immunological techniques, innovative vaccine formulation strategies, and cutting-edge molecular biology tools. Phase I will focus on (1) identifying and characterizing key immunogenic components of MDR-AB that lead to protective immunity, (2) developing a prototype vaccine formulation, and (3) conducting preliminary in vitro and in vivo evaluations to assess immunogenicity and protective efficacy. Employing a novel approach that enhances antigen selection, we aim to select bacterial proteins that induce a strong and durable immune response. As MDR-AB continues to pose a grave threat to public health, particularly in healthcare settings, the development of an effective vaccine is imperative. Our project not only addresses this urgent need but also has the potential to significantly reduce the incidence of MDR-AB infections, decrease reliance on antibiotics, and reduce the evolution of resistant strains. Successful completion of this Phase I project will lay the groundwork for Phase II studies, including extensive preclinical trials and the optimization of the vaccine formulation for clinical application. Phase I Outcomes: Expected outcomes include the identification of optimal protective subunit candidates, the establishment of a prototype vaccine formulation, and evidence of immunogenicity and efficacy in animal models. These results will provide a solid foundation for further development and testing in subsequent phases, moving us closer to a viable vaccine against MDR-AB.